The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis
Open accessAbstract
Breast cancer is a common cancer affecting a large number of patients. Notably, 5–10% of all breast cancer patients are genetically predisposed to cancers. Although the most common breast cancer susceptibility genes are BRCA1 and BRCA2, which are also associated with the risk of developing ovarian and pancreatic cancer, advances in next-generation sequencing (NGS) analysis technology enabled the discovery of several non-BRCA genes responsible for breast and ovarian cancers. Studies on hereditary breast and ovarian cancer (HBOC) involve not only determining the predisposition to developing cancer, but also considering the current treatment for breast cancer, prevention of next cancer, risk diagnosis, and adoption of protective measures for relatives. We present a comprehensive review of HBOC, which will be a useful resource in the clinical setting. Many hereditary tumors, including HBOC, are syndromes characterized by the development of different types of cancer in succession. Taking advantage of knowing predisposition of susceptibility to cancer, it is important to continue and update cancer management protocols, which includes the adoption of preventive measures, countermeasures, and treatments, to accurately assess and prevent the impact of cancer on the quality of life of the next generation of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
A breast cancer prediction model incorporating familial and personal risk factors
Tyrer, J., Duffy, S. W., & Cuzick, J. (2004) · Statistics in Medicine · doi:10.1002/sim.1668 · Cited by 1,345
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
The BRCT Domain Is a Phospho-Protein Binding Domain
Yu, X., Chini, C. C. S., He, M., Mer, G., & Chen, J. (2003) · Science · doi:10.1126/science.1088753 · Cited by 862
Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2
Parmigiani, G., Berry, D. A., & Aguilar, O. (1998) · The American Journal of Human Genetics · doi:10.1086/301670 · Cited by 753
Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response
Wang, B., Matsuoka, S., Ballif, B. A., Zhang, D., Smogorzewska, A., Gygi, S. P., & Elledge, S. J. (2007) · Science · doi:10.1126/science.1139476 · Cited by 695
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0775 · Cited by 669
BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting
Manke, I. A., Lowery, D. M., Nguyen, A., & Yaffe, M. B. (2003) · Science · doi:10.1126/science.1088877 · Cited by 651
Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H., & Ohta, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000881200 · Cited by 634
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J., Hallberg, E., Moore, R., Thomas, A., Lilyquist, J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0424 · Cited by 611
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 604
PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
Zhang, F., Ma, J., Wu, J., Ye, L., Cai, H., Xia, B., & Yu, X. (2009) · Current Biology · doi:10.1016/j.cub.2009.02.018 · Cited by 562
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., et al. (2015) · JAMA · doi:10.1001/jama.2014.5985 · Cited by 521
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing
Zhu, Q., Pao, G. M., Huynh, A. M., Suh, H., Tonnu, N., Nederlof, P. M., Gage, F. H., & Verma, I. M. (2011) · Nature · doi:10.1038/nature10371 · Cited by 485
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G., Eccles, B., Gerty, S., Durcan, L. T., Jones, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30891-4 · Cited by 481
The BOADICEA model of genetic susceptibility to breast and ovarian cancer
Antoniou, A. C., Pharoah, P. P. D., Smith, P., & Easton, D. F. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602175 · Cited by 467
BRCA1 regulates human mammary stem/progenitor cell fate
Liu, S., Ginestier, C., Charafe-Jauffret, E., Foco, H., Kleer, C. G., Merajver, S. D., Dontu, G., & Wicha, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711613105 · Cited by 461
Zhang, S., Royer, R., Li, S., McLaughlin, J. R., Rosen, B., Risch, H. A., Fan, I., Bradley, L., Shaw, P. A., & Narod, S. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.020 · Cited by 423
Timms, K. M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0475-x · Cited by 419
Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., Sharma, L., Saam, J., Lancaster, J., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 399
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., Denkert, C., Fasching, P. A., Blohmer, J. U., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
Gao, X., Fisher, S. G., & Emami, B. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00203-7 · Cited by 372
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA–ssDNA junction
Yang, H., Li, Q., Fan, J., Holloman, W. K., & Pavletich, N. P. (2005) · Nature · doi:10.1038/nature03234 · Cited by 336
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00388-9 · Cited by 296
Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2
Venkitaraman, A. R. (2014) · Science · doi:10.1126/science.1252230 · Cited by 289
Founder mutations in BRCA1 and BRCA2 genes
Ferla, R., Calò, V., Cascio, S., Rinaldi, G., Badalamenti, G., Carreca, I., Surmacz, E., Colucci, G., Bazan, V., & Russo, A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm234 · Cited by 286
Momozawa, Y., Iwasaki, Y., Parsons, M. T., Kamatani, Y., Takahashi, A., Tamura, C., Katagiri, T., Yoshida, T., Nakamura, S., Sugano, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06581-8 · Cited by 278
The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
Ramus, S. J., & Gayther, S. A. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.02.001 · Cited by 244
Sun, J., Meng, H., Yao, L., Lv, M., Bai, J., Zhang, J., Wang, L., Ouyang, T., Li, J., Wang, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3227 · Cited by 243
Li, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., Yu, B., Xu, T., Cai, H., & Zou, Q. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1465 · Cited by 234
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.120 · Cited by 232
Pijpe, A., Andrieu, N., Easton, D. F., Kesminiene, A., Cardis, E., Nogues, C., Gauthier-Villars, M., Lasset, C., Fricker, J.-P., Peock, S., et al. (2012) · BMJ · doi:10.1136/bmj.e5660 · Cited by 230
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 216
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Kotsopoulos, J., Huzarski, T., Gronwald, J., Singer, C. F., Moller, P., Lynch, H. T., Armel, S., Karlan, B., Foulkes, W. D., Neuhausen, S. L., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw177 · Cited by 197
Savage, K. I., Gorski, J. J., Barros, E. M., Irwin, G. W., Manti, L., Powell, A. J., Pellagatti, A., Lukashchuk, N., McCance, D. J., McCluggage, W. G., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.021 · Cited by 180
Valachis, A., Nearchou, A. D., & Lind, P. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2890-1 · Cited by 178
BRCA 1, a ‘complex’ protein involved in the maintenance of genomic stability
Savage, K. I., & Harkin, D. P. (2015) · The FEBS Journal · doi:10.1111/febs.13150 · Cited by 175
Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2
McLaughlin, J. R., Rosen, B., Moody, J., Pal, T., Fan, I., Shaw, P. A., Risch, H. A., Sellers, T. A., Sun, P., & Narod, S. A. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs494 · Cited by 168
The complex genetic landscape of familial breast cancer
Melchor, L., & Benítez, J. (2013) · Human Genetics · doi:10.1007/s00439-013-1299-y · Cited by 163
Song, H., Cicek, M. S., Dicks, E., Harrington, P. A., Ramus, S. J., Cunningham, J. M., Fridley, B. L., Tyrer, J. P., Alsop, J., Jimenez‐Liñan, M., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu172 · Cited by 158
Early onset HER2‐positive breast cancer is associated with germline TP53 mutations
Melhem‐Bertrandt, A., Bojadzieva, J., Ready, K. J., Obeid, E. I., Liu, D. D., Gutierrez‐Barrera, A. M., Litton, J. K., Olopade, O. I., Hortobágyi, G. N., Strong, L. C., et al. (2011) · Cancer · doi:10.1002/cncr.26377 · Cited by 142
Clinical significance of large rearrangements in BRCA1 and BRCA2
Judkins, T., Rosenthal, E., Arnell, C., Burbidge, L. A., Geary, W., Barrus, T., Schoenberger, J., Trost, J. T., WENSTRUP, R. J., & Roa, B. B. (2012) · Cancer · doi:10.1002/cncr.27556 · Cited by 134
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
Venkitaraman, A. R. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102668 · Cited by 126
Prevalence of BRCA1 Mutation Carriers among U.S. Non-Hispanic Whites
Whittemore, A. S., Gong, G. D., John, E. M., McGuire, V. M., Li, F. P., Ostrow, K. L., DiCioccio, R. A., Felberg, A., & West, D. W. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.2078.13.12 · Cited by 124
Anczuków, O., Ware, M. D., Buisson, M., Zetoune, A. B., Stoppa‐Lyonnet, D., Sinilnikova, O. M., & Mazoyer, S. (2007) · Human Mutation · doi:10.1002/humu.20590 · Cited by 122
Genomic rearrangements in BRCA1 and BRCA2: a literature review
Ewald, I. P., Ribeiro, P. L. I., Palmero, E. I., Cossio, S. L., Giugliani, R., & Ashton‐Prolla, P. (2009) · Genetics and Molecular Biology · doi:10.1590/s1415-47572009005000049 · Cited by 121
Korean Hereditary Breast Cancer Study Group, Kang, E., Seong, M., Park, S. S., Lee, J. W., Lee, J., Kim, L. S., Lee, J. E., Kim, S. Y., Jeong, J., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3377-4 · Cited by 112
Sasanuma, H., Tsuda, M., Morimoto, S., Saha, L. K., Rahman, M. M., Kiyooka, Y., Fujiike, H., Cherniack, A. D., Itou, J., Callén, E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803177115 · Cited by 110
Breast cancer risk and clinical implications for germline PTEN mutation carriers
Ngeow, J. Y. Y., Sesock, K., & Eng, C. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3665-z · Cited by 108
Palma, M. D., Domchek, S. M., Stopfer, J. E., Erlichman, J., Siegfried, J. D., Tigges-Cardwell, J., Mason, B. A., Rebbeck, T. R., & Nathanson, K. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0599 · Cited by 107
Kwong, A., Ng, E. K. O., Wong, C. L. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043994 · Cited by 103
Role of BRCA1 in brain development
Pao, G. M., Zhu, Q., Pérez‐García, C. G., Chou, S., Suh, H., Gage, F. H., O’Leary, D. D. M., & Verma, I. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400783111 · Cited by 101
Clinical spectrum and pleiotropic nature of CDH1 germline mutations
Figueiredo, J., Melo, S., Carneiro, P., Moreira, A. M., Fernandes, M. S., Ribeiro, A. S., Guilford, P., Paredes, J., & Seruca, R. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105807 · Cited by 97
BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines
Matsuda, M. L. D. L., Liede, A., Kwan, E., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10194 · Cited by 95
Lips, E. H., Laddach, N., Savola, S. P., Vollebergh, M. A., Oonk, A. M. M., Imholz, A. L. T., Wessels, L. F. A., Wesseling, J., Nederlof, P. M., & Rodenhuis, S. (2011) · Breast Cancer Research · doi:10.1186/bcr3049 · Cited by 91
Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity
Chatterjee, G., Jiménez-Sáinz, J., Presti, T., Nguyen, T. T. M., & Jensen, R. B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw242 · Cited by 71
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families
Phelan, C. M., Kwan, E., Jack, E., Li, S., Morgan, C., Aubé, J., Hanna, D., & Narod, S. A. (2002) · Human Mutation · doi:10.1002/humu.10123 · Cited by 70
Meserve, E. E. K., & Nucci, M. R. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.01.006 · Cited by 69
Kuchenbaecker, K. B., Neuhausen, S. L., Robson, M. E., Barrowdale, D., McGuffog, L., Mulligan, A. M., Andrulis, I. L., Spurdle, A. B., Schmidt, M. K., Schmutzler, R. K., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0492-9 · Cited by 68
Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families
Kang, P. C. E., Mariapun, S., Phuah, S. Y., Lim, L. S., Liu, J., Yoon, S., Thong, M., Taib, N. A. M., Yip, C. H., & Teo, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1018-5 · Cited by 64
The complex relationship between BRCA1 and ERα in hereditary breast cancer
Gorski, J. J., Kennedy, R., Hosey, A. M., & Harkin, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0640 · Cited by 61
Kim, Y. C., Zhao, L., Zhang, H., Huang, Y., Cui, J., Xiao, F., Downs, B. M., & Wang, S. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7144 · Cited by 58
Templeton, A. J., Gonzalez, L. D., Vera-Badillo, F., Tibau, A., Goldstein, R., Šeruga, B., Srikanthan, A., Pandiella, A., Amir, E., & Ocaña, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154789 · Cited by 53
Prevalence of germline TP53 mutations in HER2+ breast cancer patients
Rath, M., Masciari, S., Gelman, R. S., Miron, A., Miron, P. L., Foley, K. M., Richardson, A. L., Krop, I. E., Verselis, S. J., Dillon, D. A. R., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2375-z · Cited by 52
Multi gene panel testing for hereditary breast cancer - is it ready to be used?
Catana, A. M., Apostu, A. P., & Antemie, R.-G. (2019) · Medicine and Pharmacy Reports · doi:10.15386/mpr-1083 · Cited by 52
Regulation of centrosomes by the BRCA1-dependent ubiquitin ligase
Kais, Z., & Parvin, J. D. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.7053 · Cited by 43
The Korean Hereditary Breast Cancer Study: Review and Future Perspectives
Kang, E., & Kim, S. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.3.245 · Cited by 39
Vallard, A., Magné, N., Guy, J., Espenel, S., Rancoule, C., diao, P., Deutsch, É., Rivera, S., & Chargari, C. (2019) · British Journal of Radiology · doi:10.1259/bjr.20170657 · Cited by 27
on behalf of Korean Hereditary Breast Cancer Study Group, Kang, E., Park, H., Lee, J. W., Kim, Z., Noh, W.-C., Jung, Y. S., Yang, J., Jung, S. H., & Kim, S. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2015.164 · Cited by 25
Yoshida, R., Watanabe, C., Yokoyama, S., Inuzuka, M., Yotsumoto, J., Arai, M., & Nakamura, S. (2019) · Oncotarget · doi:10.18632/oncotarget.26852 · Cited by 25
Self-citationGermline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients Finding Founder Mutations
Choi, M. C., Heo, J. H., Jang, J., Jung, S. G., Park, H., Joo, W. D., Lee, C. M., Lee, J. H., Lee, J. M., Hwang, Y. Y., et al. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000529 · Cited by 24
Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore
Lee, A. S. G., Ho, G., Oh, P. C., Balram, C., Ooi, L. L., Lim, D. T. H., Wong, C. Y., & Hong, G. S. (2003) · Human Mutation · doi:10.1002/humu.9162 · Cited by 22
Theobald, K., Susswein, L. R., Marshall, M. L., Roberts, M. E., Mester, J. L., Speyer, D., Williams, R. N. W., Knapke, S. C., Solomon, S. R., Murphy, P. D., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6581-8 · Cited by 10
Cited by
The Lancet Commission on prostate cancer: planning for the surge in cases
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00651-2 · Cited by 738
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Metadata
- Authors
- Yoshida, R.
- Venue
- Breast Cancer
- Published
- 2020-08-29
- Volume
- 28
- Issue
- 6
- Pages
- 1167-1180
- ISSN
- 1340-6868 (ISSN-L)
- 1880-4233
- OpenAlex
- W3082133711
- Cited by
- 303
- References
- 90
- FWCI
- 19.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.